FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis
Open Access
- 22 March 2019
- journal article
- research article
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 26 (12) , 2577-2593
Abstract
Cancer cells balance with the equilibrium of cell death and growth to expand and metastasize. The activity of mammalian sterile20-like kinases (MST1/2) has been linked to apoptosis and tumor suppression via YAP/Hippo pathway-independent and -dependent mechanisms. Using a kinase substrate screen, we identified here MST1 and MST2 among the top substrates for fibroblast growth factor receptor 4 (FGFR4). In COS-1 cells, MST1 was phosphorylated at Y433 residue in an FGFR4 kinase activity-dependent manner, as assessed by mass spectrometry. Blockade of this phosphorylation by Y433F mutation induced MST1 activation, as indicated by increased threonine phosphorylation of MST1/2, and the downstream substrate MOB1, in FGFR4-overexpressing T47D and MDA-MB-231 breast cancer cells. Importantly, the specific knockdown or short-term inhibition of FGFR4 in endogenous models of human HER2+ breast cancer cells likewise led to increased MST1/2 activation, in conjunction with enhanced MST1 nuclear localization and generation of N-terminal cleaved and autophosphorylated MST1. Unexpectedly, MST2 was also essential for this MST1/N activation and coincident apoptosis induction, although these two kinases, as well as YAP, were differentially regulated in the breast cancer models analyzed. Moreover, pharmacological FGFR4 inhibition specifically sensitized the HER2+ MDA-MB-453 breast cancer cells, not only to HER2/EGFR and AKT/mTOR inhibitors, but also to clinically relevant apoptosis modulators. In TCGA cohort, FGFR4 overexpression correlated with abysmal HER2+ breast carcinoma patient outcome. Therefore, our results uncover a clinically relevant, targetable mechanism of FGFR4 oncogenic activity via suppression of the stress-associated MST1/2-induced apoptosis machinery in tumor cells with prominent HER/ERBB and FGFR4 signaling-driven proliferation.Keywords
All Related Versions
Funding Information
- Karolinska Institutet
- Cancerfonden
- Helsingin Yliopisto
- Research Council of Finland
- Magnus Ehrnroothin Säätiö
- Medicinska understödsföreningen Liv och hälsa, and the The Finnish Society of Sciences and Letters
- Terveyden Tutkimuksen Toimikunta
- Knut och Alice Wallenbergs Stiftelse
- Science for Life Laboratory
- Vetenskapsrådet
- Biotieteiden ja Ympäristön Tutkimuksen Toimikunta
This publication has 79 references indexed in Scilit:
- Okadaic Acid: A Tool to Study the Hippo PathwayMarine Drugs, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Tao-1 Phosphorylates Hippo/MST Kinases to Regulate the Hippo-Salvador-Warts Tumor Suppressor PathwayDevelopmental Cell, 2011
- The Tumor Suppressor RASSF1A Prevents Dephosphorylation of the Mammalian STE20-like Kinases MST1 and MST2Journal of Biological Chemistry, 2011
- FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase–FGFR4 complexProceedings of the National Academy of Sciences, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- c-Jun N-terminal Kinase Enhances MST1-mediated Pro-apoptotic Signaling through Phosphorylation at Serine 82Journal of Biological Chemistry, 2010
- Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppressionProceedings of the National Academy of Sciences, 2010
- Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liverProceedings of the National Academy of Sciences, 2010
- Mst1 and Mst2 Maintain Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development through Inactivation of the Yap1 OncogeneCancer Cell, 2009